A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs EFT 508 (Primary)
- Indications Haematological malignancies; Lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Effector Therapeutics
- 05 Jun 2017 According to an Effector Therapeutics media release, initial phase II efficacy data is anticipated in 2018.
- 09 Mar 2017 According to an Effector Therapeutics media release, company has dosed the first subject in this trial.
- 29 Oct 2016 Status changed from not yet recruiting to recruiting.